A selective, competitive and orally active GABAB antagonist. Displays an IC50 of 1.1 μM at GABAB, approximately 60 times that of CGP 35348 (Cat. No. 1245) and no binding affinity for GABAA at concentrations up to 100 μM.
Sold with the permission of Schering Plough Corporation
|Storage||Desiccate at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
|phosphate buffered saline||17.32||100|
Preparing Stock Solutions
The following data is based on the product molecular weight 173.21. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||5.77 mL||28.87 mL||57.73 mL|
|5 mM||1.15 mL||5.77 mL||11.55 mL|
|10 mM||0.58 mL||2.89 mL||5.77 mL|
|50 mM||0.12 mL||0.58 mL||1.15 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Bolser et al (1995) The pharmacology of SCH 50911: a novel, orally active GABA-B receptor antagonist. J.Pharmacol.Exp.Ther. 274 1393 PMID: 7562513
Hosford et al (1995) Characterization of the antiabsence effects of SCH 50911, a GABAB receptor antagonist, in the lethargic mouse, γ-hydroxybutyrate, and pentylenetetrazole models. J.Pharmacol. Exp.Ther. 274 1399 PMID: 7562514
Ong et al (1998) The morpholino-acetic acid analogue Sch 50911 is a selective GABAB receptor antagonist in rat neocortical slices. Eur.J.Pharmacol. 362 35 PMID: 9865527
If you know of a relevant reference for SCH 50911, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Selective competitive orally active GABAB antagonist Receptors SCH50911 GABAB Receptors
9 Citations for SCH 50911
Citations are publications that use Tocris products. Selected citations for SCH 50911 include:
Kreye et al (2016) Human cerebrospinal fluid monoclonal N-methyl-D-aspartate receptor autoantibodies are sufficient for encephalitis pathogenesis. Brain 139 2641 PMID: 27543972
Jaiswal et al (2015) Reduction in focal ictal activity following transplantation of MGE interneurons requires expression of the GABAA receptor α4 subunit. J Psychopharmacol 9 127 PMID: 25914623
Ding et al (2015) The reinforcing effects of ethanol within the nucleus accumbens shell involve activation of local GABA and serotonin receptors. Br J Pharmacol 29 725 PMID: 25922425
Kitagawa et al (2009) Prediction and validation of a mechanism to control the threshold for inhibitory synaptic plasticity. Mol Syst Biol 5 280 PMID: 19536203
Fritsch et al (2009) Pathological alterations in GABAergic interneurons and reduced tonic inhibition in the basolateral amygdala during epileptogenesis. Neuroscience 163 415 PMID: 19540312
Gryder et al (2005) Evidence for low GluR2 AMPA receptor subunit expression at synapses in the rat basolateral amygdala. Toxins (Basel) 94 1728 PMID: 16045445
Margeta-Mitrovic et al (2001) Ligand-induced signal transduction within heterodimeric GABA(B) receptor. Front Cell Neurosci 98 14643 PMID: 11724957
Wood et al (2000) The human GABA(B1b) and GABA(B2) heterodimeric recombinant receptor shows low sensitivity to phaclofen and saclofen. J Neurochem 131 1050 PMID: 11082110
Vogt and Nicoll (1999) Glutamate and gamma-aminobutyric acid mediate a heterosynaptic depression at mossy fiber synapses in the hippocampus. Proc Natl Acad Sci U S A 96 1118 PMID: 9927703
Do you know of a great paper that uses SCH 50911 from Tocris? If so please let us know.
Literature in this Area
GABA Receptors Scientific Review
Written by Ian Martin, Norman Bowery and Susan Dunn, this review provides a history of the GABA receptor, as well as discussing the structure and function of the various subtypes and the clinical potential of receptor modulators; compounds available from Tocris are listed.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.